Abcam, ab237712, Anti-CTLA4 antibody [CAL49]

Size: 100µL / 1mL
Anti-CTLA4 antibody [CAL49] (ab237712) is a rabbit monoclonal antibody detecting CTLA4 in Western Blot, Flow Cytometry (Intra), Flow Cytometry, IP, IHC-P . Suitable for Human, Mouse, Rhesus monkey . - Biophysical QC for unrivalled batch-batch consistency - Over 20 publications
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:CAL49,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Human, Rhesus monkey,
Applications:WB, Flow Cyt (Intra), IP, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
What is this antibody validated in?
Anti-CTLA4 antibody [CAL49] (ab237712) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Flow Cytometry (Intra), Flow Cytometry (Flow Cyt), Immunoprecipitation (IP), Immunohistochemistry (IHC-P) in Human, Mouse, Rhesus monkey samples.
What is the molecular weight of CTLA4?
Anti-CTLA4 [CAL49] (ab237712) specifically detects a band for CTLA4 (UniProt: P16410) at a molecular weight of 25kDa.
Trusted by the scientific community
Anti-CTLA4 [CAL49] (ab237712) was first used in a scientific publication in 2018 and has been cited over 20 times in peer-reviewed journals.
Reviewed by scientists
Anti-CTLA4 [CAL49] (ab237712) has over 5 independent reviews from customers.
Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10μl.
Discover our selection of trial-size antibodies.
Other related products
We have a range of other formats of antibody clone [CAL49] also available for your convenience: ab237712, Carrier free -
ab251599
, Alexa Fluor® 647 -
ab270127
, PE -
ab270128
, Alexa Fluor® 555 -
ab283489

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Purification notes-Purity >99%., Storage buffer-pH: 7.2 - 7.4 Preservative: 0.05% Sodium azide Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CTLA-4 also known as CD152 is an immune checkpoint receptor with a molecular weight of approximately 34 kDa. This protein is expressed on the surface of T-cells especially after activation and sometimes on regulatory T-cells (Tregs). CTLA-4 competes with CD28 for binding to the same ligands CD80 and CD86 on antigen-presenting cells. Unlike CD28 which stimulates T-cell activation CTLA-4 sends inhibitory signals to downregulate immune responses. By doing this CTLA-4 helps maintain immune system homeostasis and prevents autoimmune reactions.
Biological function summary
The CTLA-4 protein functions as a critical regulator of the immune system. It interacts with CD80/CD86 in a complex that effectively transmits inhibitory signals to T-cells. CTLA-4 controls the amplitude of the initial activation of T-cells ensuring that the body's immune responses are kept under control. In regulatory T-cells CTLA-4 engagement contributes to their immunosuppressive functions through which they maintain tolerance to self-antigens and prevent overactive immune reactions.
Pathways
CTLA-4 involves itself in the adaptive immune response pathways specifically the regulation of T-cell activity. CTLA-4's interaction with CD80/CD86 modulates pathways associated with TCR (T-cell receptor) signaling. When CTLA-4 binds its ligands it recruits phosphatases such as SHP-2 that dephosphorylate signaling proteins leading to the downregulation of T-cell interaction. This pathway interaction exemplifies how CTLA-4 acts in concert with proteins like CD28 to finely tune immune responses.
CTLA-4 plays a role in autoimmune diseases and cancer. The dysregulation of CTLA-4 function can lead to autoimmune disorders where the immune system attacks the body's own tissue. In cancer tumor cells may manipulate CTLA-4 pathways to evade immune surveillance. Targeted therapies like anti-CTLA-4 antibodies such as ipilimumab have been developed to block CTLA-4 aiming to enhance the immune system's ability to attack cancer cells. These treatments highlight the role of CTLA-4 in balancing immune activity and the potential to alter this balance for therapeutic benefit.